Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-03-08
2000-07-25
Tsang, Cecilia
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514579, 514588, 536 2714, 536 282, 536 278, 560313, A61K 3170
Patent
active
060937025
ABSTRACT:
A method and composition for inhibiting the spread of a retrovirus such as HIV in a human cell population in which a retrovirus such as HIV is present has been found. The spread of the retrovirus is inhibited by treatment of the cells with a synergistic combination mixture of a dideoxy-ribonucleoside excluding AZT and hydroxycarbamide.
REFERENCES:
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 5026687 (1991-06-01), Yarchoan et al.
patent: 5110600 (1992-05-01), Green
patent: 5300059 (1994-04-01), Rubinstein et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5736526 (1998-04-01), Malley et al.
patent: 5736527 (1998-04-01), Malley et al.
Meyerhans et al, "The Intracellular Nucleotide Pool Effects HIV Replication", VIII International Conference on AIDS/III STD World Congress, vol. 2, Jul. 1992, p. A22-2118.
T'Ang et al, "Optimization of the Schiff Bases of N-Hydroxy-N' aminoguanidine as Anticancer and Antiviral Agents", J. Med. Chem., vol. 28, 1985, pp. 1103-1106.
Lien, "Ribonucleotide reductase inhibitors as anticancer and antiviral agents", Progress in Drug Research, vol. 31, 1987, pp. 101-126.
Lori et al, "Hydroxyurea Inhibits HIV-1 Replication by Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1", Antiviral Res., vol. 23/Sup. 1, 1994, p. 63.
Gao et al, "Anti-HIV-1 Activity of Hydroxyurea in Combination with 2',3'-dideoxynucleosides", Clinical Research, vol. 42, No. 2, 1994, p. 280A.
Matsumoto et al, "Inhibition of RNA Synthesis by Deoxyadenosine Plus Deoxycoformycin in Resting Lymphocytes", The Journal of Immunology, vol. 131, 1983, pp. 2762-2766.
International Search Report for Internation Application No. PCT/US 94/05515.
Balzarini et al, "2',3'-Dideoxycytidine: Regulation of its Metabolism and Anti-retroviral Potency by Natural Pyrimidine Nucleosides and by Inhibitors of Pyrimidine Nucleotide Synthesis", Molecular Pharmacology, vol. 32, 1987, pp. 798-806.
Safrin et al, "Potential for Combined Therapy with 348U87, a Ribonucleotide Reductase Inhibitor, and Acyclovir as Treatment for Acyclovir-Resistant Herpes Simplex Virus Infection", Journal of Medical Virology Supplement 1, 1993, pp. 146-149.
Wilson et al, "Purinogenic Immunodeficiency Diseases--Differential Effects of Deoxyadenosine and Deoxyguanosine on DNA Synthesis in Human T Lymphoblasts", J. Clin. Invest., vol. 64, 1979, pp. 1475-1484.
Albert et al, "Deoxyadenosine Toxicity and Cell Cycle Arrest in Hydroxyurea-Resistant S49 T-Lymphoma Cells", Experimental Cell Research, vol. 179, 1988, pp. 417-428.
Perno et al, "Inhibition of Human Immunodeficiency Virus (HIV-1/HTLV-III.sub.Ba-L) Replication in Fresh and Cultured Human Peripheral Blood Monocytes/Macrophages by Azidothymidine and Related 2',3'-Dideoxynucleosides", J.of Exp. Medicine, vol. 168, 1988, pp. 1111-1125.
Fischl, "Treatment of HIV Disease in 1993/1994", AIDS Clin. Rev., vol. 94, 1993, pp 167-187.
"Ganciclovir Antagonizes the Anti-Human Immunodeficiency Virus . . . ", Medina et al., Antimicrobial Agents and Chemotherapy, May 1992, vol. 36, No. 5, pp. 1127-1130.
European Aids Clinical Society, Book of Abstracts, "Hydroxyurea as an Antiretroviral Drug in HIV Infected Patients . . . ", Simonelli et al. Fifth European Conference on Clinical Aspects, Sep. 1995.
"Anti-HIV Activity of the Combination of Didanosine and Hydroxyurea in HIV-1-Infected Individuals", Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Biron et al., vol. 10, No. 1, p 36-40, 1995.
Vila, J. et al., "1-year Follow-Up Of The Use Of Hydroxycarbamide and Didanosine in HIV Infection", The Lancet, Jul. 20, 1996, vol. 348 No. 9021; pp. 203-204.
Altman, L.K., New York Times, p. 38, Sunday, Sep. 17, 1995, "Study Challenges AZT Role as the Chief Drug for H.I.V.".
Coffin, H., Fundamental Virology 2nd Edition, pp. 545-708, Raven Press, New York, 1991, "Retroviridae and Their Replication.".
Gao, Aids Research and Human Viruses, 10(1): Supp. 3, Abstract No. 355, 1994,(Sep., 1994). "Mechanisms of the Enhanced Anti-HIV-1 Activities of 2',3'-Dideoxynucleoside Analogs by Hydroxyurea.".
Gao et al., Mol. Pharmacol., 46(4): 767-772, 1994, (Oct., 1994). "Anti-Human Immunodeficiency Virus Type 1 Activity of Hydroxyurea in Combination with 2',3'-Dideoxynucleosides.".
Goulaiouic et al., C.R. Acad. Sci. Paris, 317: 430-436, 1994, "Potentiation of 2',3'-Dideoxycytidine (ddc) by Hydroxyurea and Thymidine on the Moloney Murine Leukemia Virus (MoMLV) Early Replicative Steps.".
Goulaouic et al., Virology, 200: 87-97, 1994, "Exogenous Nucleosides Promote the Completionof MoMLV DNA Synthesis in GO-Arrested Balb c/3t3 Fibroblasts.".
Hao et al., Molecular Pharmacology, 34:431-435, 1988, "Factors Determining the Activity of 2',3'-Dideoxynucleosides in Supressing Human Immunodeficiency Virus In Vitro.".
Huber et al., J. of Biological Chemistry, 264(8): 4669-4678, 1989, (Mar. 15, 1989). "Human Immunodeficiency Virus I Reverse Transcriptase.".
Hubscher, H., Experientia, 39(1): 1-25, 1983, (Jan. 15, 1983). "DNA Polymerases in Prokaryotes and Eukaryotes: Mode of Action and Biological Implications.".
Ji et al., Mol. Gen. Genet., 226: 257-264, 1991, "Analysis of Mutagenesis Induced by a Thermolabile T4 Phage Deoxycytidylate Hydroxymethylase Suggests Localized Deoxyribonucleotide Pool Imbalance.".
Kati et al., J. of Biological Chemistry, 267(36): 25988-25997, 1992, (Dec. 15, 1992). "Mechanism and Fidelity of HIV Reverse Transcriptase.".
Langreth, The Wall Street Journal, p. B12, Nov. 21, 1995, "FDA Gives Approval to Glaxo, Sequus to Market Separate AIDS Therapies.".
Lori et al., J. of Virol., 66(8): 5067-5074, 1992, (Aug., 1992). "Viral DNA Carried by Human Immunodeficiency Virus Type 1 Virions.".
Lori et al., International Conference on Aids, 10(1): 8, Abstract No. 007b, 1994 (Aug. 7-12, 1994). "Hydroxyurea as a Novel Potent Inhibitor of HIV-1 Replication.".
Malley et al., The Lancet, 343(8908): 1292, 1994, (May 21, 1994). "Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds.".
Malley, Proc. Nat. Acad. Sci. USA, 91(23): 11017-11021, Nov. 1994, "Synergistic Anti-Human Immunodeficiency Virus Type 1 Effect of Hydroxamate Compounds with 2',3'-Dideoxyinosine in Infected Resting Human Lymphocytes.".
McCune et al., Cell, 53: 55-67, 1988, (Apr. 8, 1988). "Endoproteolytic Cleavage of gp160 is Required for the Activation of Human Immunodeficiency Virus.".
Meyerhans et al., Journal of Virology, 68(1): 535-540, 1994, (Jan., 1994). "Restriction and Enhancement of Human Immunodeficiency Virus Type 1 Replication by Modulation of Intracellular Deoxynucleosides Triphosphate Pools.".
New York Times, p. B19, Nov. 24, 1995, "Study Puts Risk of H.I.V. in Young U.S. Men at 1 in 92.".
Pegoraro et al., Experimental Cell Res., 68: 283-290, 1971, "Thymidine Kinase, Deoxycytidine Kinase and Deoxyctidylate Deaminase Activities in Phytohaemagglutinin Stimulated Human Lymphocytes.".
Popovic et al., Science, 224: 467-500, 1984, (May 4, 1984). "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-Aids.".
Robinson, W., Fundamental Virology 2nd Edition, pp. 989-1021, Raven Press, New York, 1991, "Hepadnaviridae and Their Replication.".
Stevenson et al., The EMBO Journal, 9(5): 1551-1560, 1990, "HIV-1 Replication is Controlled at the Level of T Cell Activation and Proviral Integration.".
Trono, D., J. of Virol., 66(8): 4893-4900, 1992, "Partial Reverse Transcripts in Virions from Human Immunodeficiency and Murine Leukemia Viruses.".
Varmus et al., RNA Tumor Viruses, Molecular Biology of Tumor Viruses 2nd Ed., Chapter 5, pp. 369-512, 1982, "Replication of Retroviruses.".
Gao et al., "Low Levels of Deoxynucleotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," Proc. Natl. Acad. Sci. USA, 90, 8925-8928(1990).
Biochemicals/Organic Compounds for Research and Diagnostic Reagents, Sigma Chemical Co. (catalog), St. Louis, MO, 1992, pp. 321, 341-342.
Feorino et al., "Prevention of Activation of HIV-1 by Antiviral Agents in OM-10.1 Cells," Antivira
Malley Serge D.
Vila Jorge R.
Crane L. Eric
The United States of America as represented by the Department of
Tsang Cecilia
LandOfFree
Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1336690